Related Experiment Video
Updated: Jul 1, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
Ticlopidine and platelet function in healthy volunteers
A Dembinska-Kiec1, I Virgolini, F Rauscha
1Department of Pharmacology, N. Copernicus Medical Academy, Cracow, Poland.
Thrombosis Research
|March 1, 1992
Summary
Ticlopidine therapy significantly reduced platelet aggregation and increased sensitivity to PGI2. The drug decreased platelet activity, particularly PDGF release, confirming its value in preventing atherosclerosis and related complications.
Area of Science:
- Pharmacology
- Hematology
- Cardiovascular Research
Background:
- Antiplatelet agents are crucial in managing thromboembolic disorders.
- Ticlopidine is an antiplatelet drug with a known mechanism of action.
- Further understanding of ticlopidine's effects on platelet function is warranted.
Purpose of the Study:
- To investigate the influence of a 4-week ticlopidine therapy on platelet function parameters.
- To extend knowledge on the antiplatelet activity of ticlopidine.
- To assess ticlopidine's impact on platelet aggregation and release mechanisms.
Main Methods:
- A 4-week daily administration of 500 mg ticlopidine to 10 healthy male volunteers.
- Ex-vivo platelet aggregation assays induced by ADP.
- Measurement of platelet sensitivity to prostacyclin (PGI2).
- Analysis of thromboxane B2 (TXB2) generation and platelet factor release (beta-thromboglobulin, PDGF, PF4).
Main Results:
- Ticlopidine significantly reduced ex-vivo platelet aggregation induced by ADP (p<0.01).
- Platelet sensitivity to the antiaggregatory action of PGI2 was significantly increased.
- A significant decrease in beta-thromboglobulin and PDGF release was observed (p<0.01), indicating reduced platelet activity.
- Plasma TXB2 levels decreased, although serum TXB2 and MDA formation were unaffected.
Conclusions:
- Ticlopidine therapy effectively inhibits platelet activity, particularly platelet-derived growth factor (PDGF) release.
- The beneficial effect on platelet release reaction is not linked to reduced thromboxane A2 (TXA2) formation.
- These findings support the use of ticlopidine in preventing atherosclerosis and its thromboembolic complications.
Related Concept Videos
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...